Chosa (XSAT: CHOSA)

Last close As at 22/06/2024

SEK1.10

0.07 (6.80%)

Market capitalisation

SEK79m

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress the clinical development of the technology.

Latest Insights

View More

Healthcare | Update

Chosa Oncology — Making headway in precision oncology

Healthcare | Update

RhoVac — On the home straight

Healthcare | Outlook

RhoVac — Phase IIb BRaVac study results in H122

Healthcare | Update

RhoVac — COVID-19 vaccines versus RV001

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.3 104.5 (15.4)
Relative 8.9 98.7 (27.8)
52 week high/low SEK1.3/SEK0.3

Financials

Chosa Oncology is a Scandinavian biotech looking to progress the clinical development of its cisplatin-based technology, iCIP, which consists of two core technologies: an AI-powered drug response predictor (DRP) that aims to identify the patients most likely to respond to cisplatin treatment and LiPlaCis, a liposomal cisplatin formulation with potential to improve both the safety and efficacy of conventional cisplatin. iCIP has demonstrated encouraging clinical proof-of-concept data from a Phase IIb study in metastatic breast cancer (mBC) patients, where patients with higher DRP scores were found to respond more effectively to LiPlaCis compared to those with lower DRP scores. In our view, iCIP is likely to interest pharmaceutical companies investigating novel cisplatin combination treatments. Chosa is looking to identify and secure strategic partnerships or buyers to advance iCIP into follow-on clinical studies.

Research

Update

Healthcare

RhoVac — COVID-19 vaccines versus RV001

Update

Healthcare

RhoVac — Fast Track designation granted by FDA

Update

Healthcare

RhoVac — Limited impact from COVID-19 pandemic

Update

Healthcare

RhoVac — Phase IIb study progressing to plan

Update

Healthcare

RhoVac — Phase IIb BRaVac study enrolling patients

edison tv

Healthcare

Executive interview – RhoVac

Update

Healthcare

RhoVac — Funded to execute Phase IIb study as planned

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free